How ophthalmology is pioneering the field of artificial intelligence

Retinal imaging tests are providing material to train and test decision support systems.

Outlook Therapeutics approaching FDA approval of bevacizumab-vikg for wet AMD treatment

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

AMA calls virtual special meeting, gathering June 11

Members of the medical community gather virtually to discuss current issues in the field, public health, and general business.